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A B S T R A C T 
Introduction: The use of adjuvant chemotherapy 
with S-1 (tegafur, gimeracil, and oteracil potassium) 
has been shown to improve the outcome of patients 
with gastric cancer. There are limited data on 
the tolerability of S-1 in Chinese patients. In this 
multicentre retrospective study, we aimed to assess 
the toxicity profile in local patients.
Methods: Patients with stage II-IIIC gastric 
adenocarcinoma who had undergone curative 
resection and who had received S-1 adjuvant 
chemotherapy were included in the study. 
Patient demographics, tumour characteristics, 
chemotherapy records, as well as biochemical, 
haematological, and other toxicity profiles were 
extracted from medical charts. Potential factors 
associated with grade 2-4 toxicities were identified.
Results: Adjuvant S-1 was administered to 30 
patients. Overall, 19 (63%) patients completed 
eight cycles. The most common grade 3-4 adverse 
events included neutropaenia (10%), anaemia 
(6.7%), septic episode (16.7%), diarrhoea (6.7%), 
hyperbilirubinaemia (6.7%), and syncope (6.7%). 
Dose reductions were made in 22 (73.3%) patients 
and 12 (40.0%) patients had dose delays. Univariate 
analyses showed that patients who underwent total 
gastrectomy were more likely to experience adverse 
haematological events (P=0.034). Patients with nodal 
involvement were more likely to report adverse non-
haematological events (P=0.031). Patients with a 
history of regular alcohol intake were more likely to 
have earlier treatment withdrawal (P=0.044). Lower 
body weight (P=0.007) and lower body surface area 
(P=0.017) were associated with dose interruptions.
Conclusions: The tolerability of adjuvant S-1 in our 
Adjuvant S-1 chemotherapy after curative 
resection of gastric cancer in Chinese patients: 
assessment of treatment tolerability and 
associated risk factors
New knowledge added by this study
• In line with the published data, adjuvant S-1 therapy has a tolerable toxicity profile among local patients who 
have undergone curative resection for gastric cancer. Total gastrectomy and nodal involvement are potential 
factors associated with adverse events. Lower body weight and lower body surface area are potential factors 
associated with dose interruptions. 
Implications for clinical practice or policy
• For gastric cancer patients in whom adjuvant S-1 therapy is planned, close monitoring of those who have 
identifiable risk factors may enable early recognition of adverse events during therapy. This may enable earlier 
intervention with supportive therapy and improve treatment outcome.
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patient population was similar to that in other Asian 
patient populations. The awareness of S-1–related 
toxicities and increasing knowledge of potential 
associated factors may enable optimisation of S-1 
therapy.
This version may differ 
from the print version.
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華籍胃癌患者接受癌切除後輔助S-1化療的 
耐受性和相關危險因素
楊明明、林嘉安、羅麗柔、李智仁、蔣子樑、區國雄、 
巫國輝、蘇子謙、林國智、吳偉裳、李良
引言：研究發現使用S-1（tegafur、gimeracil和oteracil potassium）
的輔助化療可改善胃癌患者的預後。然而，S-1在華籍患者的耐受性
數據仍很有限。這項多中心回顧性研究旨在評估本地胃癌患者對S-1
化療的耐受性和相關危險因素。
方法：研究對象包括完成手術切除和S-1輔助化療的ii至iiic期胃癌患
者。從病人紀錄找出患者的人口學數據、腫瘤特徵、化療紀錄，以及
生化、血液學和其他毒性特徵，並確定與2-4級毒性副作用相關的潛在
因素。
結果：共30位胃癌患者接受S-1輔助化療。19名患者（63%）完成8個
週期的S-1輔助化療。最常見的3至4級不良事件包括嗜中性白血球減
少症（10%）、貧血（6.7%）、感染性事件（16.7%）、腹瀉（6.7%）、
高膽紅素血症（6.7%）和暈厥（6.7%）。22名患者（73.3%）的藥物
劑量有減少，而12名患者（40.0%）延遲化療。單因素分析顯示，全
胃切除的患者更可能有不良骨髓副作用（P=0.034）。有淋巴結受累
的患者更可能產生不利的非骨髓副作用（P=0.031）。曾定期飲酒的
患者可能比預期提早停止S-1治療（P=0.044）。影響治療劑量的因素
包括較低體重（P=0.007）和較小的體表面積（P=0.017）。
結論：本地胃癌患者對S-1的耐受性與其他亞洲患者相若。了解S-1相
關的副作用和潛在的相關因素可以優化S-1治療。
Introduction
Gastric cancer is the second most common cause 
of cancer-related mortality worldwide, with 988 000 
new cases and 736 000 deaths per year.1 Surgery is 
the main treatment for operable gastric cancer but 
recurrence rates are high and about 40% to 80% of 
patients develop relapsed disease after surgery. The 
use of adjuvant chemotherapy has been shown to 
improve patient outcome.2-5 After curative resection, 
common adjuvant chemotherapy regimens that have 
been recently adopted in many parts of Asia include 
oral administration of S-1 (tegafur, gimeracil, 
and oteracil potassium) based on the Adjuvant 
Chemotherapy Trial of S-1 for Gastric Cancer 
(ACTS-GC) study conducted in Japan,4 as well as 
oxaliplatin-capecitabine combination chemotherapy 
based on the Capecitabine and Oxaliplatin Adjuvant 
Study in Stomach Cancer study.5 These studies have 
shown that adjuvant S-1 for 1 year or oxaliplatin-
capecitabine combination chemotherapy for 6 
months following curative gastrectomy with D2 
lymph node dissection increases both overall survival 
(OS) and relapse-free survival in pathological stage 
II or III gastric cancer.4,5 
 S-1 is an oral anticancer agent comprising 
tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and 
oteracil potassium (Oxo) in molar ratios of 1:0.4:1.6 
Tegafur is a prodrug of 5-fluorouracil (5-FU); CDHP 
is a potent reversible inhibitor of 5-FU degradation; 
and Oxo is an inhibitor of the enzyme orotate 
phosphoribosyltransferase (OPRT) that catalyses 
the phosphorylation of 5-FU.6 Pharmacokinetic 
analyses have confirmed that S-1 has potent anti-
tumour activity, and oral S-1 administration 
results in a similar serum concentration of 5-FU to 
intravenous 5-FU whilst sparing patients the need 
for continuous intravenous infusion of 5-FU and 
consequent toxicity.7 Nonetheless early studies have 
also shown that toxicity profiles may differ between 
Asian and non-Asian patients. In earlier studies in 
Japanese patients, the dose-limiting toxicity was 
bone marrow suppression that occurred prior to 
gastrointestinal adverse events. In contrast, studies 
in non-Asian patients revealed that diarrhoea 
associated with abdominal discomfort and cramping 
was the principal dose-limiting toxicity and bone 
marrow suppression was not.8 This might be due 
to the varied activity of OPRT between different 
populations. In fact, OPRT activates 5-FU in the 
bowel mucosa; patients with higher OPRT activity 
might be expected to experience a higher incidence 
of gastrointestinal adverse effects prior to bone 
marrow toxicity.9 
 In the ACTS-GC study, the adverse events of 
adjuvant S-1 were reported to be generally mild, 
with 65.8% of patients being able to complete the 
planned 1 year of therapy.4 While it has been known 
that patients in the West have a different toxicity 
profile to their Japanese counterparts,10 there are 
limited data on tolerability of S-1 among Chinese 
patients. In this multicentre retrospective study, we 
aimed to assess the toxicity and tolerability profile 
of Hong Kong Chinese patients with gastric cancer 
who had received adjuvant S-1 chemotherapy.
Methods
This was a retrospective study carrying out between 
June 2013 and February 2016, and involved six local 
centres in Hong Kong: Pamela Youde Nethersole 
Eastern Hospital, Princess Margaret Hospital, Prince 
of Wales Hospital, Tuen Mun Hospital, Queen 
Mary Hospital, and United Christian Hospital. 
This study has been approved by the institutional 
ethics committee of each participating centre with 
patient consent waived. Patients with stage II-IIIC 
gastric adenocarcinoma according to American 
Joint Committee on Cancer,11 who had completed 
curative surgical treatment and who had undergone 
S-1 adjuvant chemotherapy, were included. Patients 
with stage IV disease and who had had prior therapy 
with S-1 in the neoadjuvant setting were excluded. 
 Adjuvant S-1 was started at least 3 weeks after 
curative surgery. The intended dose of S-1 was based 
on that published in the ACTS-GC trial,4 and was 
40 mg/m2 twice daily for 4 weeks followed by 2 
weeks of rest for each cycle. Specifically, during the 
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treatment weeks, patients with body surface area 
(BSA) of <1.25 m2 received 80 mg daily; those with 
BSA of 1.25 m2 to <1.5 m2 received 100 mg daily; and 
those with BSA of ≥1.5 m2 received 120 mg daily. As 
clinically indicated, dose reductions were considered 
one dose level at a time; in general, one dose level 
reduction refers to reducing the prior daily dose by 
20 mg, eg from 120 mg to 100 mg daily. As renal 
impairment has been associated with increased 
incidence of myelosuppression, dose reduction 
by one dose level was made in patients who had a 
creatinine clearance of 40-49 mL/min. A maximum 
of eight 6-weekly cycles were administered. The 
dose of S-1 was reduced in patients with significant 
toxicities, as assessed by the respective clinician- 
in-charge. Complete and differential blood count 
and serum chemistry were performed before each 
6-week cycle. All patients had mid-cycle follow-
up with complete and differential blood count and 
serum chemistry in the first cycle.
 Patient charts were reviewed by investigators 
at each centre for background information. S-1 
chemotherapy records, as well as biochemical and 
haematological profiles, were extracted. Adverse 
events were graded according to the National 
Cancer Institute’s Common Terminology Criteria 
for Adverse Events (version 3.0).12 Adverse events 
were documented during chemotherapy and for 28 
days after the last dose of S-1. Dose interruption was 
defined as a need for either any dose delay and/or 
dose reduction.
 Clinical characteristics are summarised as 
number of patients and percentage (%) for categorical 
variables, and medians with ranges for continuous 
variables. The frequency of adverse events was 
tabulated. Factors independently associated with 
adverse events, dose interruptions, or earlier 
withdrawal of S-1 were identified using the Pearson’s 
Chi squared (χ2) test or the Fisher’s exact test if the 
expected number in any cell was less than five for 
categorical data or any cell with an expected count 
of less than one for categorical data, and t test or 
Wilcoxon rank-sum test for continuous data. A two-
sided P value of <0.05 was considered significant. 
All statistical analyses were performed with SAS, 
version 9.3 (SAS Institute Inc, Cory [NC], US).
 Disease-free survival (DFS) was calculated 
as the period from the date of surgery to the date 
of recurrence or death from any cause; OS was 
calculated as the period from the date of surgery to 
the date of death from any cause. Both DFS and OS 
were estimated using the Kaplan-Meier method.
Results
Characteristics of patients
Thirty patients met the eligibility criteria in the six 
centres during the study period and were enrolled in 
this study. Their baseline demographic and clinical 
TABLE 1.  Baseline demographic and clinical characteristics (n=30)
Characteristics Median (range) or No. (%)
Age (years) 65.6 (27-83)
Sex
Male 18 (60.0)
Female 12 (40.0)
ECOG performance status
0 8 (26.7)
1 19 (63.3)
2 3 (10.0)
HBsAg status
Positive 2 (6.7)
Negative 28 (93.3)
Prior cancer
Yes 1 (3.3)
No 29 (96.7)
Height on diagnosis (cm) 160 (145-182)
Weight on diagnosis (kg) 55.6 (45-83)
BMI on diagnosis (kg/m2) 21.9 (19-30)
BSA at diagnosis (m2) 1.6 (1.4-2.0)
Ever smoker
Yes 6 (20.0)
No 24 (80.0)
Ever regular alcohol intake
Yes 5 (16.7)
No 25 (83.3)
Site of tumour
Antrum 12 (40.0)
Body 9 (30.0)
Body and antrum 3 (10.0)
Fundus and body 1 (3.3)
Gastroesophageal junction 5 (16.7)
Type of gastrectomy
Total 11 (36.7)
Partial 19 (63.3)
D dissection
D1 2 (6.7)
D2 26 (86.7)
N/A 2 (6.7)
Cancer stage, TNM classification
II 19 (63.3)
IIIA 2 (6.7)
IIIB 7 (23.3)
IIIC 2 (6.7)
Tumour stage
T1 1 (3.3)
T2 5 (16.7)
T3 15 (50.0)
T4 9 (30.0)
Nodal stage
N0 11 (36.7)
N1 5 (16.7)
N2 7 (23.3)
N3 7 (23.3)
No. of LN resected 31 (12-77)
No. of LN involved 2 (0-33)
Creatinine clearance (mL/min)
≥60 23 (76.7)
<60 7 (23.3)
Time from surgery to cycle 1 day 1 of S-1 (days) 42 (22-162)
Abbreviations: BMI = body mass index; BSA = body surface area; ECOG = Eastern 
Cooperative Oncology Group; HBsAg = surface antigen of the hepatitis B virus; LN = 
lymph nodes; N/A = not available; S-1 = administration of tegafur, gimeracil, and oteracil 
potassium; TNM = tumour node metastasis
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characteristics are shown in Table 1. 
 There were 18 males and 12 females with a 
median age of 65.6 years. Of the patients, 27 (90%) 
had ECOG (Eastern Cooperative Oncology Group) 
performance status of 0 to 1. Total gastrectomy 
was performed in 11 (36.7%) patients and partial 
gastrectomy in 19 (63.3%). D2 dissection was 
performed in 26 (86.7%) patients and two had D1 
dissection; the details of two other patients were 
unknown. The median number of lymph nodes 
resected was 31. Cancer stage II disease was present 
in 19 (63.3%) patients and stage III in 11 (36.7%).
 Of the 30 patients, two (6.7%), two (6.7%), 
one (3.3%), two (6.7%), one (3.3%), three (10%), and 
19 (63.3%) completed one, two, three, four, five, 
six, and eight cycles of S-1 adjuvant chemotherapy, 
respectively. At the time of data cut-off on 29 February 
2016, one patient was still on S-1, having completed 
six cycles of treatment. The reasons for treatment 
withdrawal included toxicities (n=5, 16.7%), patient 
refusal (3, 10%), recurrence (2, 6.7%), and worsening 
of pre-existing Parkinson’s disease (1, 3.3%).
Patient survival
The median follow-up period was 25.3 months 
(range, 16.3-29.2 months). Three patients died and 
two experienced recurrence (lung and peritoneum). 
The 3-year DFS and OS rates were 80.2% and 85.9%, 
respectively (Fig).
Tolerability data
Table 2 presents the haematological and non-
haematological adverse events experienced during 
treatment. Grade 3-4 haematological adverse events 
included neutropaenia (n=3, 10%), leukopaenia 
(1, 3.3%), and anaemia (2, 6.7%). Grade 3-4 non-
haematological adverse events included non-
neutropaenic septic episode (16.7%), diarrhoea 
(6.7%), hyperbilirubinaemia (6.7%), syncope (6.7%), 
reduced left ventricular ejection function (3.3%), 
gouty attack (3.3%), hypokalaemia (3.3%), subacute 
intestinal obstruction (3.3%), and urticaria (3.3%). 
 Of note, 10 patients developed a septic episode; 
apart from one patient with grade 3 neutropaenic 
fever, the others were non-neutropaenic. Of the 
latter, four had grade 3 toxicity, four had grade 2, 
and one had grade 1 toxicity; in one patient with 
grade 2 toxicity, the infection was due to pulmonary 
tuberculosis. This latter patient had a history of 
ischaemic heart disease and he also developed grade 
3 reduced left ventricular ejection function whilst on 
S-1, as noted above.
 Two out of 30 patients were found to be 
positive for hepatitis B surface antigen. Of these two, 
one was prescribed prophylactic antiviral therapy 
and liver function remained normal apart from one 
isolated episode of grade 2 hyperbilirubinaemia 
that resolved spontaneously without other hepatic 
dysfunction; the other patient did not receive 
prophylactic antiviral therapy but his liver function 
remained normal throughout S-1 therapy. 
 There were no treatment-related deaths.
Dose interruptions 
Of the 30 patients, 17 (56.7%) were commenced on 
a lower-than-intended dose of S-1. The reason for 
reducing the first dose was: impaired renal function 
(n=6; with creatinine clearance ranging from 41-48 
mL/min), concern of toxicity (6), aged over 70 
years (4), and borderline performance status (1); 
four of these patients had further dose reduction in 
subsequent cycles. Of the other 13 patients who had 
the full S-1 dose in cycle 1, five had a dose reduction 
from cycle 2 onwards. 
 Dose delays occurred in 12 (40%) patients; 
these were due to delayed bone marrow recovery 
(n=3), hypokalaemia (2, including 1 who also had 
delayed bone marrow recovery), diarrhoea (2), sepsis 
(2), hypoglycaemia (1), impaired renal function (1), 
reduced weight (1), and abdominal pain (1).
Risk factor analysis
Potential risk factors for adverse events were 
assessed (Table 3). Univariate analysis showed that 
total gastrectomy was significantly associated with 
haematological adverse events; 90.9% of patients 
who had total gastrectomy in contrast to 52.6% of the 
patients who had partial gastrectomy experienced 
grade 2-4 adverse events (P=0.034). On univariate 
analysis, nodal status was significantly associated 
with non-haematological adverse events; 76.2% of 
patients who experienced grade 2-4 adverse events 
had nodal disease, while only 33% of those who 
had grade 0-1 adverse events had nodal disease 
(P=0.031). 
 Potential risk factors for earlier withdrawal 
FIG.  Kaplan-Meier estimates of disease-free survival (DFS) and overall survival (OS)
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of S-1 and dose interruptions (dose reductions 
and/or dose delays) were assessed (Table 4). For 
earlier S-1 withdrawal, patients who had a history 
of regular alcohol intake were significantly more 
likely to have earlier treatment withdrawal than 
non-drinkers (80% vs 28%; P=0.044), while ever-
smokers also had a tendency, though insignificant, 
for earlier withdrawal than never-smokers (67% vs 
29%; P=0.095). For dose interruptions, univariate 
analysis showed lower body weight (P=0.007) and 
lower BSA (P=0.017) were significant associated 
factors, while lower body mass index (BMI) also 
had an increased tendency, though insignificant, 
for dose interruptions (P=0.055). The median body 
weight, BMI, and BSA of those patients who had dose 
interruptions was 54.5 kg, 21.4 kg/m2, and 1.54 m2,
respectively; the corresponding figures for those 
who did not require dose interruptions were 64.0 kg, 
24.8 kg/m2, and 1.67 m2, respectively.
Discussion
Our study results indicate that adjuvant S-1 
chemotherapy is feasible for our local patients after 
curative resection of gastric cancer. With increased 
awareness of the associated toxicity, S-1 can be 
offered safely as standard adjuvant therapy. The 
toxicities experienced by the studied patients were 
in line with previous findings in Asian patients.4,12,13 
Grade 3-4 haematological adverse events included 
thrombocytopaenia and anaemia. Grade 3-4 non-
haematological adverse events that occurred in 5% 
or more of the patients included non-neutropaenic 
septic episode, diarrhoea, hyperbilirubinaemia, and 
syncope.
 Previous studies have investigated factors 
associated with adverse events during S-1 therapy. 
In a Korean study of 305 patients given adjuvant S-1 
therapy,13 total gastrectomy was reported to be an 
independent risk factor for grade 3-4 haematological 
toxicities and age >65 years was an independent risk 
factor for grade 3 non-haematological toxicities. 
Independent risk factors for withdrawal and dose 
reductions included age >65 years and male gender. 
Total gastrectomy has also been reported to be 
associated with a significantly greater risk of serious 
adverse events in another study of Taiwanese gastric 
cancer patients receiving adjuvant S-1.14 
 The reason for the higher incidence of serious 
adverse events in patients who underwent total 
gastrectomy whilst receiving S-1 treatment is 
unknown. In an earlier study, a higher incidence of 
adverse reactions was observed among patients who 
received S-1 as adjuvant treatment after gastrectomy, 
compared with those who had unresectable or 
recurrent gastric cancer. The investigators suggested 
the limitation in food intake soon after extensive 
surgery as a possible cause of exacerbation of adverse 
reactions such as anorexia and nausea, and proposed 
TABLE 2.  Haematological and non-haematological adverse events (all grades) 
Adverse event Grade (n=30)
0 1 2 3 4
Haematological
Leukopaenia 8 17 4 0 1
Neutropaenia 19 3 5 3 0
Anaemia 0 14 14 2 0
Thrombocytopaenia 18 12 0 0 0
Biochemical
Hypokalaemia 20 9 0 0 1
Hyperbilirubinaemia 15 8 5 2 0
Hypoalbuminaemia 29 0 1 0 0
Raised creatinine 19 9 2 0 0
Hyperkalaemia 26 3 1 0 0
Hypoglycaemia 29 0 1 0 0
Uraemia* 20 9 0 0 0
Raised alanine transaminase 24 6 0 0 0
Raised alkaline phosphatase 22 8 0 0 0
Hypernatraemia 22 8 0 0 0
Hyponatraemia 22 8 0 0 0
Other non-haematological
Septic episode 20 1 4 5 0
Diarrhoea 9 15 4 2 0
Syncope 28 0 0 2 0
Pain (non-specified) 25 3 1 1 0
Reduced LVEF 29 0 0 1 0
Gouty attack 29 0 0 1 0
Subacute intestinal obstruction 29 0 0 1 0
Urticaria 29 0 0 1 0
Anorexia 19 8 3 0 0
Rash 23 5 2 0 0
Weight loss 27 1 2 0 0
Pain (abdomen) 28 0 2 0 0
Hand-foot syndrome 20 9 1 0 0
Nausea 21 8 1 0 0
Fatigue 28 1 1 0 0
Headache 28 1 1 0 0
Vomiting 28 1 1 0 0
Ascites 29 0 1 0 0
Constipation 29 0 1 0 0
Thirsty 29 0 1 0 0
Stomatitis 18 12 0 0 0
Pigmentation 22 8 0 0 0
Insomnia 28 2 0 0 0
Dry skin 28 2 0 0 0
Fever 28 2 0 0 0
Sensory neuropathy 28 2 0 0 0
Pruritus 28 2 0 0 0
Alopecia 29 1 0 0 0
Bloating, abdominal 29 1 0 0 0
Dizziness 29 1 0 0 0
Dry eyes 29 1 0 0 0
Dyspnoea 29 1 0 0 0
Abdominal discomfort 29 1 0 0 0
Hypotension 29 1 0 0 0
Lacrimation 29 1 0 0 0
Lower gastrointestinal haemorrhage 29 1 0 0 0
Menorrhagia 29 1 0 0 0
Musculoskeletal: right groin hernia 29 1 0 0 0
Musculoskeletal: buttock discomfort 29 1 0 0 0
Oedema 29 1 0 0 0
Sexual: right breast swelling and tenderness 29 1 0 0 0
Abbreviation: LVEF = left ventricular ejection function
* Unknown data in 1 case
  #  Yeo et al #
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Abbreviations: BMI = body mass index; BSA = body surface area; ECOG = Eastern Cooperative Oncology Group; HBsAg = surface antigen of the hepatitis 
B virus; LN = lymph nodes; N/A = not available; S-1 = administration of tegafur, gimeracil, and oteracil potassium; TNM = tumour node metastasis
* Data are shown as median (range) or No.
† For continuous data, the P value was obtained by t test or by Wilcoxon rank-sum test if the continuous data were not normally distributed. For category 
data, the P value was obtained by Chi squared test or Fisher’s exact test if the cells had an expected count of <5 or any cell had an expected count of <1
TABLE 3.  Univariate analysis of risk factors for grade 2-4 adverse events
Risk factor Grade 2-4 haematological adverse events* Grade 2-4 non-haematological adverse 
events*
Grade 0-1 (n=10) Grade 2-4 (n=20) P value† Grade 0-1 (n=9) Grade 2-4 (n=21) P value†
Age (years) 67.5 (54-83) 64.5 (27-78) 0.1363 64.0 (33-83) 66.0 (27-78) 0.9172
Gender 0.3058 0.2855
Male 6 12 6 12
Female 4 8 3 9
ECOG performance status 0.4114 0.0717
0 2 6 4 4
1 6 13 3 16
2 2 1 2 1
HBsAg status 0.4598 0.4828
Positive 1 1 0 2
Negative 9 19 9 19
Height on diagnosis (cm) 158 (145-167) 161 (150-182) 0.0936 164 (148-170) 160 (145-182) 0.9097
Weight on diagnosis (kg) 56.5 (48-64.1) 55.6 (45-82.8) 0.9649 54.8 (48-71.9) 56.3 (45-82.8) 0.9099
BMI on diagnosis (kg/m2) 22.7 (20.3-30.4) 21.0 (19.0-28.9) 0.1588 22.2 (19.7-25.0) 21.4 (19.0-30.4) 0.6669
BSA at diagnosis (m2) 1.55 (1.39-1.70) 1.57 (1.38-1.95) 0.6127 1.58 (1.39-1.83) 1.55 (1.38-1.95) 0.7003
Ever smoker 0.2304 0.3084
Yes 3 3 1 5
No 7 17 8 16
Ever regular alcohol intake 0.3400 0.3780
Yes 1 4 1 4
No 9 16 8 17
Type of gastrectomy 0.0338 0.1937
Total 1 10 2 9
Partial 9 10 7 12
D dissection 0.5301 0.5365
D1 1 1 1 1
D2 9 17 8 18
N/A 0 2 0 2
Cancer stage, TNM classification 0.1268 0.7369
II 5 14 6 13
IIIA 2 0 1 1
IIIB 3 4 2 5
IIIC 0 2 0 2
Tumour stage 0.8964 0.6503
T1 0 1 0 1
T2 2 3 1 4
T3 5 10 4 11
T4 3 6 4 5
Nodal stage 0.8488 0.0314
N0 4 7 6 5
N1 1 4 0 5
N2 3 4 3 4
N3 2 5 0 7
No. of LN resected 28.5 (12-59) 31.5 (12-77) 0.4409 23.0 (12-50) 32.0 (14-77) 0.2046
No. of LN involved 2.5 (0-9) 1.5 (0-33) 0.9463 0.0 (0-6) 3.0 (0-33) 0.1007
Creatinine clearance (mL/min) 0.3427 0.2469
≥60 8 15 6 17
<60 2 5 3 4
Time from surgery to cycle 1 day 1 of S-1 (days) 0.2274 0.2865
>42 6 9 4 11
≤42 4 11 5 10
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Abbreviations: BMI = body mass index; BSA = body surface area; ECOG = Eastern Cooperative Oncology Group; HBsAg = surface antigen of the hepatitis 
B virus; LN = lymph nodes; N/A = not available; S-1 = administration of tegafur, gimeracil, and oteracil potassium; TNM = tumour node metastasis
* Data are shown as median (range) or No.
† For continuous data, the P value was obtained by t test or by Wilcoxon rank-sum test if the continuous data were not normally distributed. For category 
data, the P value was obtained by Chi squared test or Fisher’s exact test if the cells had an expected count of <5 or any cell had an expected count of <1
TABLE 4.  Univariate analysis of risk factors for earlier S-1 withdrawal and dose interruptions
Risk factor Earlier S-1 withdrawal Dose interruptions
Received 8 
cycles of S-1 
(n=19)*
Withdrawal of 
S-1 before cycle 
8 (n=11)*
P value† No dose 
interruptions 
(n=6)*
Dose 
interruptions 
(n=24)*
P value†
Age (years) 66 (37-78) 65.0 (27-83) 0.4845 65.5 (63-71) 65.5 (27-83) 0.3252
Gender 0.2884 0.1732
Male 11 7 5 13
Female 8 4 1 11
ECOG performance status 0.6575 0.4712
0 4 4 1 7
1 13 6 5 14
2 2 1 0 3
HBsAg status 0.3931 0.6345
Positive 2 0 0 2
Negative 17 11 6 22
Height on diagnosis (cm) 160 (145-169) 160 (148-182) 0.3762 167 (145-182) 160 (148-169) 0.1603
Weight on diagnosis (kg) 56.9 (45-80.5) 52.8 (48-82.8) 0.5468 64.0 (56.9-82.8) 54.5 (45-80.5) 0.0065
BMI on diagnosis (kg/m2) 22.2 (19.0-30.4) 20.6 (19-25.7) 0.3656 24.8 (20.0-30.4) 21.4 (19-28.9) 0.0548
BSA at diagnosis (m2) 1.56 (1.39-1.78) 1.53 (1.38-1.95) 0.9485 1.67 (1.55-1.95) 1.54 (1.38-1.78) 0.0170
Ever smoker 0.0950 0.2684
Yes 2 4 2 4
No 17 7 4 20
Ever regular alcohol intake 0.0440 0.4474
Yes 1 4 1 4
No 18 7 5 20
Type of gastrectomy 0.1221 0.2154
Total 5 6 1 10
Partial 14 5 5 14
D dissection 0.0973 0.5616
D1 2 0 0 2
D2 17 9 6 20
N/A 0 2 0 2
Cancer stage, TNM classification 0.6993 0.1735
II 12 7 2 17
IIIA 2 0 1 1
IIIB 4 3 3 4
IIIC 1 1 0 2
Tumour stage 0.1079 0.5840
T1 0 1 0 1
T2 5 0 0 5
T3 10 5 4 11
T4 4 5 2 7
Nodal stage 0.9528 0.4695
N0 7 4 1 10
N1 3 2 2 3
N2 5 2 2 5
N3 4 3 1 6
No. of LN resected 31 (12-51) 36 (19-77) 0.2912 32 (19-59) 31 (12-77) 0.6591
No. of LN involved 2 (0-33) 2 (0-20) 0.1000 2.5 (0-9) 1.0 (0-33) 0.6336
Creatinine clearance (mL/min) 0.3141 0.1700
≥60 15 8 6 17
<60 4 3 0 17
Time from surgery to cycle 1 day 1 of S-1 (days) 0.7048 1.0000
>42 9 6 3 12
≤42 10 5 3 12
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that a delay in the start of drug administration after 
gastrectomy may prevent such adverse events.15 In 
another study, Taiwanese patients received palliative 
S-1 for advanced gastric cancer at a median initial 
dose of 37.0 mg/m2. Twelve patients had single-
dosing pharmacokinetic study on day 1, and seven 
took part in a multiple-dosing pharmacokinetic 
study on day 28. The results indicated that the 
steady-state pharmacokinetics of 5-FU, CDHP 
and Oxo could be predicted from single-dose 
pharmacokinetic study. Six patients who underwent 
gastrectomy had a similar pharmacokinetic profile 
to another six patients who did not undergo 
gastrectomy.16 Nonetheless, definitive data regarding 
the pharmacokinetic profile of S-1 components 
in patients who underwent different degrees of 
gastrectomy are lacking. 
 Other factors that have been reported to be 
associated with treatment-related adverse events 
include low body mass and impaired renal function.16 
These were supported by the present study in which 
lower body weight, BMI, and BSA were associated 
with an increased likelihood of dose interruptions. 
Earlier reports have shown that impaired renal 
function will reduce CDHP clearance and result in a 
prolonged high concentration of 5-FU in plasma, and 
thereby lead to more severe myelosuppression.8,17 
Although impaired renal function was not identified 
as a risk factor for adverse events in this study, it 
has to be noted that all patients who had subnormal 
creatinine clearance were offered S-1 at lower doses 
at treatment initiation; this could have prevented the 
occurrence of severe adverse events. 
 The present study was limited by its 
retrospective nature and the limited number 
of patients accrued. Although there is a lack of 
information about patient co-morbidities, the 
current data suggest that patients who had a history 
of regular alcohol intake had an increased likelihood 
of earlier treatment withdrawal. The survival data 
are immature due to short follow-up. The findings, 
however, lend support to a published report on the 
acceptable toxicity profile and tolerability of S-1 as 
adjuvant therapy after curative gastric surgery for 
gastric cancer.4,13,14 Potential risk factors for severe 
adverse events are suggested. Due to the small 
sample size and retrospective nature of this study, a 
prospective study with a larger patient population is 
needed to confirm these findings. An awareness of 
treatment-related adverse events as well as potential 
associated factors may aid clinicians in managing 
patients in whom S-1 therapy is planned, and 
thereby improve treatment compliance and clinical 
outcome. 
Conclusions
Adjuvant S-1 therapy has a tolerable toxicity profile 
among local patients who have undergone curative 
resection for gastric cancer. For gastric cancer 
patients in whom adjuvant S-1 therapy is planned, 
those with identifiable risk factors should be closely 
monitored for adverse events during treatment. This 
may enable earlier intervention with supportive 
therapy and optimise treatment outcome.
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